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Abstract
Ewing sarcoma (ES) is an aggressive pediatric bone cancer with low five-year survival
rates, particularly with recurrent disease because ES often becomes resistant to chemotherapy in
these recurrences. Cannabidiol (CBD) has been identified as a potentially promising therapeutic
for patients with ES. In other cancer types, CBD has demonstrated effects on two major proteins
that contribute to chemotherapy resistance. The first, Poly (ADP-ribose) Polymerase I (PARP1),
is a DNA damage repair enzyme that is overexpressed in recurrent ES. Though chemotherapy
induces DNA damage in these cancer cells, the high levels of PARP1 facilitate repair of the
DNA, allowing the mutated DNA to be duplicated and subsequent proliferation of the cancer to
occur. CBD has been shown to cleave PARP1 in colon, prostate, and breast cancer cell lines.
The second, survivin, is a protein that inhibits apoptosis, is overexpressed in ES, and its
reduction leads to decreased growth in ES cell lines. The hypothesis of this study was that CBD
would both cleave PARP1 and downregulate survivin expression in the A673 ES cell line.
Enzyme-linked immunosorbent assay (ELISA) data demonstrated cleavage of PARP1 by CBD at
concentrations of 30µM and higher. However, survivin expression was increased at the same
concentrations. These data suggest further investigation into the use of CBD to modulate
pathways known to contribute to chemotherapy resistance is warranted in an effort to improve
the prognosis for patients with recurrent ES.
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Introduction

Ewing’s sarcoma (ES) is a highly aggressive pediatric bone cancer with low survival
rates. It is the second most common bone cancer and is considered a high-grade malignancy,
meaning ES cells tend to grow and spread at a faster rate than in less aggressive (low-grade)
cancers (Durer and Shaikh, 2022). Because of this, approximately 34% of patients with ES show
metastasis at diagnosis (Meshram, Kaur, and Hura, 2019). The ES family tumors consists of
undifferentiated small round cell tumors that appear most often in the bone and rarely in the soft
tissue. These tumors are rare, accounting for less than 10% of all human malignancies, but are
extremely aggressive. They often occur in the long bones and pelvis where they can quickly
metastasize to the bone marrow, lung, and other tissues (Ross et al., 2013). ES is generally
treated with an aggressive regimen of multimodal therapy including chemotherapy, radiation,
and surgery. Chemotherapy is used before surgery in order to combat any micro-metastases that
may exist at the time of diagnosis and to reduce the volume of the primary tumor in order to
facilitate its surgical removal (Ozaki, 2015). Despite this, overall five-year survival rate of
patients with ES is only 62%, localized survival rate is 82%, regional is 70%, and distant is
merely 39%. ES is often extremely resistant to chemotherapy in recurrent cases (Heinen et al.,
2016). The ineffectiveness of chemotherapy results in a poor prognosis for patients. Recurrence
occurs in at least 25% of patients with initially localized disease and 50-80% of patients with
initially metastatic disease depending on the area of metastasis (Gaspar et al., 2015).
Chemotherapy induces DNA damage to cancer cells meaning that the DNA damage response
(DDR) will be initiated when damage occurs. Prognosis for these patients would be aided by the
discovery and implementation of new drugs with anti-tumor properties.

Ewing sarcoma is characterized by a recurrent balanced chromosomal translocation
(Grünewald et al., 2018). Chromosomal translocation occurs when a chromosome breaks into
fragments which then reattach to other chromosomes. Recurrent chromosomal translocation
occurs in many cancer cells. The translocation in ES results in the fusion of the gene EWSR1
with one of several members of the Ets family of transcription factors, most commonly, the gene
FLI1 in 85-90% of cases (Zucman et al., 1992). The normal role of the EWSR1 is to code for the
protein EWS, which functions in cellular processes, including gene expression, cell signaling,
and RNA processing and transport (Law, Cann, and Hicks, 2006). FLI protein binds DNA and
activates transcription of local genes (Kwon et al., 2013). In the remainder of ES cases, EWSR1
fuses with other members of this transcription factor family ERG, ETV1, or E1AF (Wang et al.,
2007). The ERG fusion provided the first example of different but related gene fusions occurring
in phenotypically and clinically similar human solid tumors (Delattre et al., 1992). Not only do
tumors expressing the EWSR1–FLI1 fusion make up the largest number of ES cases, but also
tumors expressing this fusion are more inclined to have high cell to cell adhesion that switches to
cell-matrix adhesion, resulting in higher rates of migration and metastasis (Delattre et al., 1992).
Resistance to recurring disease in ES is at least partly due to the high expression of two
proteins that are involved with DNA repair. Traditional chemotherapy, such as the single-agent
chemo drug temozolomide, induce death in cancer cells by causing DNA damage. This damage
is detected during the G1/S restriction checkpoint, and apoptosis should be initiated. However, in
cells expressing high levels of PARP or survivin, this checkpoint can be bypassed, and the cells
survive, making them resistant to the chemotherapy. Ewing sarcoma heavily expresses PARP,
and this expression is regulated by the EWS-FLI1 fusion protein (Gill et al., 2015). Poly (ADPribose) polymerases (PARP) are a group of ADP-ribosyl transferase enzymes. These enzymes

transfer ADP-ribose from NAD+ onto their target proteins. This enzymatic function is
responsible for regulating multiple cell processes, such as DNA repair and DNA replication.
PARP inhibition with the drug Olaparib has been shown to have anti-tumor activity in breast,
ovary, and prostate cancers. However, exposure to Olaparib treatment causes a DNA damage
repair response through homologous recombination (Gill et al., 2015). The protein, Survivin,
belongs to the inhibitor of apoptosis (IAP) family. Survivin downregulates apoptosis by
inhibiting caspase activity. Depletion of Survivin results in the accumulation of tumor protein 53
(p53), which functions as a tumor suppressing gene and assists in preventing cancer. Survivin
depletion has also been shown to decrease the expression of multiple genes related to DNA
repair through homologous recombination (Véquaud et al., 2015). The resulting defects to
homologous recombination cause an increased dependency on PARP to preform DNA repair.
Survivin-depleted cells are shown to be sensitive to PARP inhibition due to this increased
dependency (Véquaud et al., 2015). In Ewing sarcoma, impairment of homologous
recombination genes has enhanced sensitivity to olaparib (Gill et al., 2015). Olaparib inhibits
PARP by trapping PARP1 and PARP2 at the sites of DNA damage. Olaparib binds PARP1 and
locks the enzymes on to damaged DNA, which results in the halt of PARP1 DNA repair function
(Murai et al., 2012). High expression of PARP1 provides an explanation to the nature of Ewing
sarcoma’s hypersensitivity to PARP inhibition. Survivin-depletion combined with PARP
inhibition shows promise in causing cell death in Ewing sarcoma.
An emerging group of compounds from the Cannabis sativa plant has been shown to
affect expression of PARP and survivin in various cancers. Cannabidiol (CBD) has been heavily
studied in relation to enhancing the prognosis of cancer patients. CBD has been shown to induce
higher levels of apoptosis. For example, a study on colorectal cancer showed that CBD was used

alongside TNF-related apoptosis-inducing ligand (TRAIL) to increase the level of apoptosis in
multiple colorectal cancer cell lines (Kim et al., 2019). Also, CBD has anti-tumor activity. In
head and neck squamous cell carcinoma, CBD was shown to have cytotoxic and antitumorigenic properties in mouse models (Go et al., 2020). CBD’s effects on PARP have also
been documented. CBD caused increased cleavage of PARP in head and neck squamous cell
carcinoma resulting in an increase in apoptosis (Go et al., 2020). CBD-induced cleavage of
PARP1 results in the weakening of the cancer’s ability to repair DNA. Cleavage of PARP would
be especially effective in treatment of Ewing sarcoma considering its sensitivity to PARP
inhibition. Also, inhibition of survivin by CBD would be a promising development due to the
cancer cells reliance on its ability to halt apoptosis. A decrease in PARP and survivin expression
in Ewing sarcoma through treatment by CBD could have promising effects on the levels of
apoptosis present in this cancer cell line according to research done in this area.
In this study, we intend to observe the effects a weakened DDR has on ES cell viability.
PARP cleavage has been documented in neck squamous cell carcinoma (Go et al., 2020),
because of this, we hypothesize that CBD will be effective at cleaving PARP in Ewing sarcoma.
We also hypothesize that CBD will inhibit survivin expression in Ewing sarcoma due to CBD’s
ability to increase apoptosis in colorectal cancer (Kim et al., 2019). This study aims to better
understand the role of CBD in limiting the DNA damage response of Ewing sarcoma through
inhibition of the enzyme PARP and the protein survivin. Therefore, the specific aims and
hypotheses of this project are to determine the ability of CBD to cleave PARP1 in ES cells. We
hypothesize CBD will induce cleavage of PARP1 in ES cells. Also, to determine the ability of
CBD to alter expression levels of survivin in ES cells. We hypothesize CBD will decrease
expression of survivin in ES cells.

Materials and Methods

Reagents
The CBD used for treatment was diluted from a 100 mM stock to a 10 mM stock in
ethanol. Olaparib was reconstituted by taking five grams of powder and adding 1.15 mL of
DMSO until the powered was completely dissolved. Both reagents were kept at -20° C in
microcentrifuge tubes until required for experimentation.

Cell Culture
A673 cells were purchased from the American Type Culture Collection (ATCC). The cell
line used were A673 Ewing sarcoma cancer cells. The cells were cultured in Dulbecco’s
Modified Eagle's Medium (DMEM). The DMEM used was supplemented with 10% fetal bovine
serum (FBS). Also, the DMEM was treated with 10 mL of penicillin-streptomycin (Pen-Strep)
solution. The cells were kept in a humified incubator set to 37° C with a 5% CO2 atmosphere to
imitate human body conditions.

Cell Viability: MTT Assay
MTT assays were used to determine the percentage of viable cells left after treatment.
A673 cells were plated in a 24-well plate the first day. The second day of the assay these cells
were treated. The control groups were ethanol and dimethyl sulfoxide (DMSO) treated at a
concentration of 40μM. The treatment groups were 2.5, 5, 10μM CBD and 10, 20, 40μM
Olaparib. In this experiment, it was important that cell death did not occur, so the assay was
performed 18 hours after treatment. MTT reagent is added to the cells and incubated for an hour.

The MTT reagent is then aspirated off and DMSO is added to the cells. The cells are placed on
an orbital shaker for 10 minutes and are then placed in a plate reader to have their absorbance
measured. Absorbance is measured at a wavelength of 570 nm.

PARP ELISA
The ELISA used to measure cleaved PARP was the Invitrogen™ human PARP 214/215
ELISA kit. Cell lysates were treated in a 6-well plate, scrapped off the plate, and then
centrifuged to isolate a cell pellet for each sample. These cell pellets were then resuspended in
cell extraction buffer and the protease inhibitor, PMSF. Cell extraction lasted 30 minutes and
then the samples were centrifuged again for 10 minutes at 13,000 RPM and 4° C. The
supernatant of the resulting solution was then taken and frozen at -80° C until needed. The
ELISA was performed according to the manufacturer's protocol (Cleaved PARP [214/215]
ELISA kit catalog number KHO0741 (96 tests)). The absorbance of each well was measured at
450 nm in the plate reader.

Survivin ELISA
The ELISA used to measure survivin expression was the R&D Systems™ Human
Survivin ELISA microplate. Cell supernatants were taken from treated cells plated on a 6-well
plate. After treatment, 500 μL of supernatant was removed from each sample and added to
microcentrifuge tubes. This supernatant was then stored at -80° C until needed. The samples
were centrifuged before the ELISA was performed to remove any cell debris still suspended in
the liquid. The ELISA was performed according to the manufacturer’s protocol (Human survivin

immunoassay quantikine ® ELISA). The absorbance of each well was measured at 450 nm in the
plate reader.

Statistical Analysis
Statistical analysis was performed using GraphPad Prism 8.0 (GraphPad Software, Inc.;
San Diego, CA). All graphs made for each ELISA and MTT assay were created using this
software. One-way analysis of variance (ANOVA) was used to evaluate statistical differences in
each graph. Statistical differences were measured between each bar in each graph using Tukey’s
t-test.

Data and Results

MTT Assay
A MTT assay was used to measure the cell viability of post-treatment ES cells at 18
hours. The treatment groups consisted of 2.5, 5, 10μM CBD, 10, 20, 40μM olaparib, and an
ethanol control at a 40μM concentration. The MTT assay showed all treatment groups
maintaining a percentage of cell viability between 95-100% after 18 hours of treatment (Fig.1).
Statistical analysis showed no pairwise statistical differences. No significant death occurred, so
the time of lysate and supernatant collection would be 18 hours post-treatment.

PARP ELISA
A cleaved PARP ELISA was used to measure the efficacy at which CBD cleaves PARP.
The treatment groups tested for the initial cleaved PARP ELISAs were 40μM ethanol, 40μM
olaparib, and 40μM CBD. The treatment groups for the second ELISAs were 50μM ethanol and
10, 20, 30, 40, 50μM CBD. The initial PARP ELISA results show that cleaved PARP was
present at higher concentrations than the Olaparib or ethanol controls (Fig.2). The second set of
PARP ELISA results showed that PARP cleavage induced by CBD causes a threshold effect at
40μM and concentration of cleaved PARP increases with the concentration of CBD the cells
were treated with (Fig.3).

Survivin ELISA
An ELISA was used to measure survivin expression in CBD treated cancer cells. The
treatment groups for the initial set of survivin ELISAs were 40μM ethanol, 10μM CBD, and

40μM CBD. The treatment groups for the second ELISAs were 50μM ethanol and 10, 20, 30,
40, 50μM CBD. The first set of survivin ELISA results showed survivin expression increasing at
higher concentrations of CBD (Fig.4). The second set of results expanded on this to show a
variety of concentrations of CBD in which survivin expression increased with higher
concentrations of CBD and then significantly increased at a threshold of 40μM CBD (Fig.5).

Discussion

The results reported in this study demonstrate the efficacy of CBD to cleave PARP1 and
induce a survivin response in the A673 ES cell line. CBD cleaved PARP1 at significantly higher
levels compared to the negative controls, ethanol and olaparib (Fig. 2). When measuring if CBD
cleavage of PARP1 was dose dependent, it was noted that CBD cleaved PARP at dosages
starting at 30mM (Fig. 3). Additionally, a cleavage threshold was observed at the 40μM
concentration (Fig. 3) meaning that concentration of cleaved PARP1 increased significantly from
the 30mM concentration to the 40μM concentration. Based on these findings, the alternative
hypothesis that CBD would induce PARP1 cleavage was accepted. CBD treatment did not have
the predicted effect on survivin expression. Survivin expression was significantly increased at
the 40μM concentration of CBD when compared to the ethanol control and the lower
concentration of 10μM (Fig. 4). Survivin expression was tested for dose dependence at varying
concentrations of CBD, and a threshold effect was observed at the 40μM concentration (Fig. 5).
Concentration of survivin increased at higher dosages of CBD, so we found no evidence to reject
the null hypothesis. CBD at a concentration of 40μM illustrated a threshold effect in both
cleaved PARP and survivin expressions. CBD demonstrated the ability to cleave the enzyme
PARP1 in the A673 ES cell line.
Ewing sarcoma is characterized by high expression levels of both survivin and PARP1.
PARP inhibition has resulted in increased apoptosis and deficiency of the DNA damage response
in ES cell lines. Specifically, use of the PARP inhibitor, olaparib, results in increased sensitivity
to chemotherapy drugs, such as temozolomide. For instance, mouse models were tested for
efficacy of chemotherapy on PARP-depleted tumors. This resulted in increased sensitivity to the

chemotherapy drugs irinotecan and temozolomide and increased survival in mice treated with
olaparib before chemotherapy treatment (Stewart et al., 2014). Trapping of PARP through the
use of olaparib also results in cytotoxic activity due to formation of PARP-DNA complexes
(Murai & Pommier, 2019). These complexes result in the inactivation of PARP allowing cell
cycle checkpoints, specifically those at the S phase, to halt progression of the cell cycle and
trigger apoptosis (Murai & Pommier, 2019). ES cell lines also heavily express survivin making it
a strong target protein. In a study performed to measure the effects of survivin expression in
patients with ES, patients with high levels of expression demonstrated higher rates of
progression, recurrence, and death (Mahmoud et al., 2022). There is also evidence that survivin
plays a role in the DDR by influencing proteins involved in homologous recombination
(Véquaud et al., 2015). Downregulation of survivin in different cancer cell lines has been shown
to increase cell death and impair DNA repair. Survivin depletion in breast cancer cell lines
resulted in impairment of genes related to the homologous recombination pathway and the
weakening of the pathway itself (Véquaud et al., 2015). Depletion of survivin also lead to
accumulation of the tumor suppressor, p53, and an increased sensitivity to PARP inhibition due
to the defects caused to the homologous recombination pathway and resulting reliance on PARP
to repair DNA damage (Véquaud et al., 2015). Additionally, the survivin suppressant, YM155,
was shown to induce PARP-dependent cell death, called parthanatosis (Zhao et al., 2015). Drugs
targeted at the DDR, and specifically PARP and survivin, induced cell death and exhibited antitumor activity. The results provided by various literature necessitate additional drug treatments
that target the expression of these proteins.
Cannabinoids have demonstrated anti-tumor properties including increased cell death and
decreased proliferation. CBD promoted the expression of an intercellular adhesion molecule that

caused lung cancer cells to adhere to lymphokine-activated killer cells resulting in the lysis of the
cancerous cells (Haustein et al., 2014). CBD also influenced cell signaling pathways to trigger
apoptosis and autophagy. In breast cancer cell lines, CBD induced stress in the endoplasmic
reticulum (ER) and inhibited signaling of important cell division molecules, such as mTOR, and
also mediated autophagy and apoptosis (Shrivastava et al., 2011). CBD has function as a PARP
inhibitor in head and neck squamous cell carcinoma. In this same cancer, CBD sensitized cancer
cells to chemotherapy drugs and induced apoptosis and autophagy (Go et al., 2020). In colorectal
cancer, CBD was used to sensitize cancer cells to the ligand, TRAIL, which regulates apoptosisrelated proteins, resulting in ER stress-related apoptosis and reduced expression of PARP (Kim
et al., 2019). CBD has been used to sensitize various cancer cell lines to chemotherapy drugs and
other anti-tumor agents (Go et al., 2020, Haustein et al., 2014). CBD also played a role in
limiting the impact of DDR in multiple cancer cell lines through the cleavage of PARP (Go et
al., 2020, Kim et al., 2019). The results presented in the literature and in this study illustrated that
CBD may serve as a potential adjuvant therapy for various tumors.
Since the EWS/FLI1 oncogene was discovered, the prognosis of patients with Ewing
sarcoma has seen little improvement. Due to the aggressive nature of this cancer and likelihood
of recurrence to occur in ES patients, additional options for treatment are needed to improve
overall prognosis of patients. The high expression of the DNA repair proteins, survivin and
PARP, have played a role in the aggressiveness of ES tumors. Cannabidiol has been used to
sensitize multiple cancer cell lines to different treatments. This study reported the ability of CBD
to cleave PARP at high concentrations. However, there is a lack of literature surrounding CBD
and its ability to inhibit these essential DDR-related proteins. Further study is needed to clarify
CBD and its effects. For example, it is unknown how CBD affects survivin expression in

comparison to other anticancer agents. A study comparing survivin expression in different
chemotherapy drugs and CBD would further the understanding of how CBD affects this
apoptosis-inhibiting protein. Furthermore, survivin and PARP1 are known to be upregulated in
ES, however, the expression of these proteins has not been quantified. Future studies would
benefit from having understood baseline expression levels for PARP1 and survivin in ES. CBD
has exhibited promise in impairing the DDR in the A673 ES cell line. Further research is needed
to fully understand the effects of CBD on this pathway.
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Figure 1. MTT Assay; this assay was used to establish time points at which proteins could be
measured when no death had yet occurred. For each bar on this graph, n=6. A cell viability of
95-100% was maintained between all samples. No significant death occurred. For this graph,
p=0.027 with no pairwise statistical differences. F7,40=2.577.

Figure 2. Initial PARP ELISA; in this data set, we saw that there was significant difference
between the concentration of cleaved PARP between the CBD treatment group and the ethanol
and Olaparib controls. For each bar on this graph, n=7. The one-way ANOVA performed
calculated p<0.0001. Each bar on this graph was test for significance between treatment groups.
Columns with the same letters have no difference, while columns with different letters are
statistically different. Asterisks represent significant difference based on p value. F2,15=38.57.

Figure 3. Follow-up PARP ELISA; this data set compared a variety of different CBD dosages.
For each bar on this graph, n=6. We observed that there was a threshold at the 40μM CBD
treatment at which PARP cleavage is highly expressed. There was significant difference between
the dosages at 40 and 50μM and the lower dosages. The one-way ANOVA performed calculated
p<0.0001. Each bar on this graph was test for significance between treatment groups. Columns
with the same letters have no difference, while columns with different letters are statistically
different. Asterisks represent significant difference based on p value. F7,30=560.713.

Figure 4. Initial Survivin ELISA; this ELISA compared an ethanol control with two treatment
groups, CBD 10μM and CBD 40μM. At 40μM, CBD caused a survivin response in the ES cells.
For each bar on this graph, n=9. The one-way ANOVA performed calculated p<0.0001. Each bar
on this graph was test for significance between treatment groups. Columns with the same letters
have no difference, while columns with different letters are statistically different. Asterisks
represent significant difference based on p value. F2,18=69.86.

Figure 5. Follow-up Survivin ELISA; this ELISA compared differing dosages of CBD. For
each bar on this graph, n=6. At 40μM CBD, we saw a threshold where the survivin response was
much stronger than that of the lower dosages of CBD. The one-way ANOVA performed
calculated p<0.0001. Each bar on this graph was tested for significance between treatment
groups. Columns with the same letters have no difference, while columns with different letters
are statistically different. Asterisks represent significant difference based on p value.
F5,24=707.548.
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Figure 6. PARP Standard Curve; this is a standard curve used to calculate cleaved PARP
concentrations from measured absorbance values. Cleaved PARP standard curves are
characterized by a plateau effect as absorbance and concentration increase.
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Figure 7. Survivin Standard Curve; this a standard curve used to calculate survivin
concentration from measured absorbance values. Survivin standard curves are characterized by a
consistent increase in absorbance and concentration.
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Appendix A: Raw Data
Raw data includes the initial absorbance values, graphed values, and treatment groups
corresponding to each set of values. Each set of data is titled with its corresponding figure
number.
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